Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109–5942, USA.
Breast. 2011 Oct;20 Suppl 3:S162-4. doi: 10.1016/S0960-9776(11)70317-4.
Adjuvant systemic therapy (AST) clearly reduces mortality from breast cancer. The decision to recommend AST is based on prognosis and prediction. Clinically useful prognostic factors have historically been principally anatomic, based on size of the tumor and the presence or absence axillary lymph node metastases. More recently, multi-parameter assays have become incorporated into prognostic calculations, principally in patients who are ER positive. None has been established to have clinical utility in patients who are ER negative.
辅助全身治疗（AST）显然降低了乳腺癌的死亡率。推荐 AST 的决定基于预后和预测。历史上，临床上有用的预后因素主要是基于肿瘤大小和腋窝淋巴结转移的有无的解剖学因素。最近，多参数检测已被纳入预后计算中，主要是在 ER 阳性的患者中。在 ER 阴性的患者中，尚未确定任何具有临床实用性的指标。
